Медицинская библиотека · Alimentary pharmacology & therapeutics · 2026
Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease.
Garre Ana, Nuñez Ortiz Andrea, Rubio Saioa, Diz-Lois Palomares María Teresa, Riestra Sabino, Alonso-Galán Horacio, Fernández-Salgado Estela, Ferreiro-Iglesias Rocío, Vela Milagros, Ponferrada Díaz Ángel, Sánchez Rodríguez Eugenia, Hernández Vicent, Arias García Lara, Barrio Jesús, Huguet José María, Ginard Daniel, Rivero Montserrat, Vera Isabel, Alonso-Abreu Inmaculada, Benítez José Manuel, Aguas Mariam, Rodríguez-Lago Iago, Calvet Xavier, Fernández-Salazar Luis, Echarri Ana, Arroyo María Teresa, Navarro-Llavat Mercè, Vega Pablo, Sierra Mónica, Guerra Del Río Elena, Vicente Raquel, Casanova María José, Navarro Pablo, de Zarate Jone Ortiz, Trastoy Pilar Varela, Spicakova Katerina, Gutiérrez Ana, Martín-Arranz María Dolores, Piñero Concepción, Hernández-Martínez Álvaro, Torrella Cortés Emilio, Marrero José Miguel, Lorente Poyatos Rufo H, Martí Romero Lidia, Bosch Orencio, Duque José María, Aceituno Montserrat, Fernández Hipólito, Crespo Suarez Belén, Fuentes Coronel Ana María, Pozzati Liliana, Robledo Pilar, Sesé Abizanda Eva, Herreros Martínez Belén, Jiménez Nuria, López Serrano Pilar, Sampedro Manuela Josefa, Bermejo Fernando, Lucendo Alfredo J, Muñoz Vicente Margarita, Menacho Margarita, Ramírez Palanca José Joaquín, Camargo Raquel, Carmona Amalia, Torra Alsina Sandra, Calafat Margalida, Forcelledo José Luis F, Nerín de la Puerta Juan, Nicolás Isabel, Opio Verónica, Ber Yolanda, Bouhmidi Abdel, Abraldes Bechiarelli Alfredo, Castaño-Milla Carlos, Cruz Noelia, Gordillo Jordi, Sapiña Amparo, López Alina, Rodríguez Mondéjar Silvia, Novella Durán María Teresa, Botella Belén, Kutz Marcos, Kolle Lilyan, Marín-Jiménez Ignacio, Martínez-Cerezo Francisco J, Irisarri Rebeca, Iyo Eduardo, Roncero Óscar, Sabat Miriam, Torres Domínguez Yolanda, Ledezma Cesar, Zapata Eva María, Alcalá María José, Lluis Laia, Martínez Pascual Cristina, Blázquez Gómez Isabel, Hernández Luis, Mata Laura, Monrobel Ana, Hernández Camba Alejandro, Maroto Nuria, Tejada María, Galve María Luisa, Montealegre María, Hervías Daniel, Soler Marta, Gómez-Valero José Antonio, Barreiro-de Acosta Manuel, Soto Escribano Pilar, Cabriada José Luis, Ceballos Daniel, Esteve Maria, García Rodríguez Alba, Royo Vanesa, Gomollón Fernando, Verdejo Gil Cristina, Nos Pilar, de Francisco Ruth, García María José, Dueñas Sadornil Carmen, Rodríguez Cristina, Sicilia Beatriz, Fernandez-Felix Borja M, Gisbert Javier P, Chaparro María, EpidemIBD Group of GETECCU
СтатьяПеревод пока не подготовлен
Аннотация
AIMS: This study aimed to describe the characteristics of newly diagnosed inflammatory bowel disease (IBD) patients and to analyse their clinical course within the first 5 years after diagnosis, including the need for surgery, hospitalisations and treatments.
METHODS
This prospective and large multicentre incident cohort registry in Spain enrolled adults diagnosed with Crohn's disease (CD), ulcerative colitis (UC) or unclassified IBD (IBD-U) in 2017 and followed them for 5 years.
RESULTS
A total of 3301 patients were enrolled: 1526 with CD, 1633 with UC and 142 with IBD-U. Their median age at diagnosis was 43 years (interquartile range 31-56) and approximately 50% were male. Within 5 years post-diagnosis, 30% received biologics or JAK inhibitors (JAKi), 34% were hospitalised at least once and 9% underwent surgery. The cumulative incidence of biologic/JAKi treatment, hospitalisations and surgeries was higher among CD patients. Use of biologics/JAKi correlated with a more aggressive CD phenotype, greater UC extent and younger age at diagnosis. Biologics/JAKi treatment was associated with lower hospitalisation risk in both CD (Hazard ratio [HR] = 0.4, 95% confidence interval [CI] = 0.2-0.6) and UC patients (HR = 0.5, 95% CI = 0.2-0.9). However, it was not associated with the risk of abdominal surgery in CD but was linked to an increased risk of surgery in UC (HR = 11.9, 95% CI = 4.6-30.4).
CONCLUSIONS
This large multicentre cohort demonstrated a higher use of biologics/JAKi during the first 5 years after IBD diagnosis than previously reported. Treatment with biologics/JAKi was associated with reduced risk of hospitalisation. However, under current clinical practice patterns, this therapeutic approach did not translate into lower risk of abdominal surgery.
Для цитирования: Garre Ana, Nuñez Ortiz Andrea, Rubio Saioa, Diz-Lois Palomares María Teresa, Riestra Sabino, Alonso-Galán Horacio, Fernández-Salgado Estela, Ferreiro-Iglesias Rocío, Vela Milagros, Ponferrada Díaz Ángel, Sánchez Rodríguez Eugenia, Hernández Vicent, Arias García Lara, Barrio Jesús, Huguet José María, Ginard Daniel, Rivero Montserrat, Vera Isabel, Alonso-Abreu Inmaculada, Benítez José Manuel, Aguas Mariam, Rodríguez-Lago Iago, Calvet Xavier, Fernández-Salazar Luis, Echarri Ana, Arroyo María Teresa, Navarro-Llavat Mercè, Vega Pablo, Sierra Mónica, Guerra Del Río Elena, Vicente Raquel, Casanova María José, Navarro Pablo, de Zarate Jone Ortiz, Trastoy Pilar Varela, Spicakova Katerina, Gutiérrez Ana, Martín-Arranz María Dolores, Piñero Concepción, Hernández-Martínez Álvaro, Torrella Cortés Emilio, Marrero José Miguel, Lorente Poyatos Rufo H, Martí Romero Lidia, Bosch Orencio, Duque José María, Aceituno Montserrat, Fernández Hipólito, Crespo Suarez Belén, Fuentes Coronel Ana María, Pozzati Liliana, Robledo Pilar, Sesé Abizanda Eva, Herreros Martínez Belén, Jiménez Nuria, López Serrano Pilar, Sampedro Manuela Josefa, Bermejo Fernando, Lucendo Alfredo J, Muñoz Vicente Margarita, Menacho Margarita, Ramírez Palanca José Joaquín, Camargo Raquel, Carmona Amalia, Torra Alsina Sandra, Calafat Margalida, Forcelledo José Luis F, Nerín de la Puerta Juan, Nicolás Isabel, Opio Verónica, Ber Yolanda, Bouhmidi Abdel, Abraldes Bechiarelli Alfredo, Castaño-Milla Carlos, Cruz Noelia, Gordillo Jordi, Sapiña Amparo, López Alina, Rodríguez Mondéjar Silvia, Novella Durán María Teresa, Botella Belén, Kutz Marcos, Kolle Lilyan, Marín-Jiménez Ignacio, Martínez-Cerezo Francisco J, Irisarri Rebeca, Iyo Eduardo, Roncero Óscar, Sabat Miriam, Torres Domínguez Yolanda, Ledezma Cesar, Zapata Eva María, Alcalá María José, Lluis Laia, Martínez Pascual Cristina, Blázquez Gómez Isabel, Hernández Luis, Mata Laura, Monrobel Ana, Hernández Camba Alejandro, Maroto Nuria, Tejada María, Galve María Luisa, Montealegre María, Hervías Daniel, Soler Marta, Gómez-Valero José Antonio, Barreiro-de Acosta Manuel, Soto Escribano Pilar, Cabriada José Luis, Ceballos Daniel, Esteve Maria, García Rodríguez Alba, Royo Vanesa, Gomollón Fernando, Verdejo Gil Cristina, Nos Pilar, de Francisco Ruth, García María José, Dueñas Sadornil Carmen, Rodríguez Cristina, Sicilia Beatriz, Fernandez-Felix Borja M, Gisbert Javier P, Chaparro María, EpidemIBD Group of GETECCU. Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease.. Alimentary pharmacology & therapeutics. 2026. DOI: 10.1111/apt.70987.
Подготовка и перевод публикацииОбработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.
MedElevator
Войти в исследования